Results 71 to 80 of about 72,428 (200)

Sorafenib fails to trigger ferroptosis across a wide range of cancer cell lines

Cell Death and Disease, 2021
Sorafenib, a protein kinase inhibitor approved for the treatment of hepatocellular carcinoma and advanced renal cell carcinoma, has been repeatedly reported to induce ferroptosis by possibly involving inhibition of the cystine/glutamate antiporter, known
Jiashuo Zheng, Mami Sato, Eikan Mishima, Hideyo Sato, B. Proneth, M. Conrad   +5 more
semanticscholar   +1 more source

m6A‐Modified circRAPGEF1 Interaction with IGF2BP3 Promotes Hepatocellular Carcinoma Progression via Reprogramming Aspartate Metabolism

Advanced Science, EarlyView.
In hepatocellular carcinoma (HCC), the m6A‐modified circRAPGEF1 destabilizes ASS1 mRNA via competitive binding to IGF2BP3, driving aspartate metabolic reprogramming in liver cancer stem cells (LCSCs). This cascade enhances stemness properties and reduces sorafenib sensitivity in LCSCs, thereby identifying circRAPGEF1 as a promising therapeutic target ...
Juanyi Shi, Sintim Mui, Yongcong Yan, Shaomin Liu, Kai Wen, Chuanchao He, Huoming Li, Hao Liao, Meng Tao, Jiahua Wen, Weidong Wang, Xiaoding Xu, Zhenyu Zhou, Zhiyu Xiao   +13 more
wiley   +1 more source

Inhibition of pMAPK14 Overcomes Resistance to Sorafenib in Hepatoma Cells with Hepatitis B Virus

Translational Oncology, 2018
Hepatitis B virus (HBV) targets the liver and is a major driver for liver cancer. Clinical data suggest that HBV infection is associated with reduced response to treatment with the multi-kinase inhibitor sorafenib, the first available molecularly ...
Dvora Witt-Kehati, Alexandra Fridkin, Maya Bitton Alaluf, Romy Zemel, Amir Shlomai   +4 more
doaj   +1 more source

FNDC5 Causes Resistance to Sorafenib by Activating the PI3K/Akt/Nrf2 Pathway in Hepatocellular Carcinoma Cells

Frontiers in Oncology, 2022
In this study, we aimed to reveal the resistance mechanism of hepatocellular carcinoma (HCC) cells to sorafenib by exploring the effect of FNDC5 on sorafenib-induced ferroptosis in HCC cells.
Huayuan Liu, Lei Zhao, Mengya Wang, Kexin Yang, Zhipeng Jin, Chengjian Zhao, Guangjun Shi   +6 more
doaj   +1 more source

Clathrin Light Chain B Drives Hepatocellular Carcinoma Progression Through Dual Mechanisms: Small Extracellular Vesicle‐Mediated Angiogenesis and the NF‐κB–PCLAF Signaling Axis

Advanced Science, EarlyView.
Clathrin Light Chain B (CLTB) drives hepatocellular carcinoma progression through dual pathways: intracellularly, it activates the NF‐κB–PCLAF axis to enhance small extracellular vesicle (sEV) uptake and tumor proliferation; extracellularly, CLTB‐enriched sEVs bind SH3KBP1 to inhibit its degradation, inducing angiogenesis and vascular leakage ...
Xiaoke Sun, Junchen Guo, Ning Zhao, Guanghua Cui, Yun Bai, Meijuan Ding, Yi Xu, Yu Yang   +7 more
wiley   +1 more source

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial

Gut, 2019
Objective This trial compared the efficacy and safety of transarterial chemoembolisation (TACE) plus sorafenib with TACE alone using a newly established TACE-specific endpoint and pre-treatment of sorafenib before initial TACE.
M. Kudo, K. Ueshima, M. Ikeda, T. Torimura, N. Tanabe, H. Aikata, N. Izumi, T. Yamasaki, S. Nojiri, K. Hino, H. Tsumura, T. Kuzuya, N. Isoda, K. Yasui, Hajime Aino, A. Ido, Naoto Kawabe, K. Nakao, Y. Wada, O. Yokosuka, K. Yoshimura, T. Okusaka, J. Furuse, N. Kokudo, K. Okita, P. Johnson, Y. Arai   +26 more
semanticscholar   +1 more source

Avidity‐Based Capture of PD‐L1‐Expressing Exosomes via Dendrimer–Peptide Conjugates: A Nanoengineered Platform for Enhanced Prediction of Immunotherapy Response

Advanced Science, EarlyView.
This study introduces a dendrimer‐peptide conjugate platform (G7‐pPDL1) for avidity‐based capture of PD‐L1‐expressing exosomes. The system exhibits enhanced binding kinetics and exosome capture efficiency, enabling accurate prediction of immunotherapy outcomes.
Jiah Lee, Dongjun Shin, Chae Yeon Son, Hanbit Kang, Jung Hyun Choi, Hyun Sung Park, Seha Bang, Lucia Kim, Tae Hee Lee, Hyuk Soo Eun, Michael J Poellmann, Woo‐jin Jeong, Dong Hyung Kim, Jun Hyeok Lim, Seungpyo Hong, Jiyoon Bu   +15 more
wiley   +1 more source

Spatial Transcriptomics and snRNA‐seq Expose CAF Niches Orchestrating Dual Stromal‐Immune Barriers in Hepatocellular Carcinoma

Advanced Science, EarlyView.
HmmyCAFs may form a triple immunosuppressive niche: possibly secrete ECM (POSTN, etc.) as physical barriers to block CD8⁺ T cells, induce CD8⁺ T exhaustion via those molecules, and use HIF‐1α‐driven metabolism to create acidic, nutrient‐poor microenvironments that suppress T cells.
Yingxue Li, Changxiang Huan, Haoting Sun, Wei Zhang, Zhen Guo, Chuanyu Li, Jia Yao, Zhiqi Zhang, Shizhe Yu, Qiongzhu Dong, Lunxiu Qin, Jinze Li, Lianqun Zhou   +12 more
wiley   +1 more source

High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo

BMC Cancer, 2017
Background Primary liver cancer is a lethal malignancy with a high mortality worldwide. Currently, sorafenib is the most effective molecular-targeted drug against hepatocellular carcinoma (HCC). However, the sorafenib resistance rate is high.
Yinzong Xiao, Lunquan Sun, Yongming Fu, Yan Huang, Rongrong Zhou, Xingwang Hu, Pengcheng Zhou, Jun Quan, Ning Li, Xue-Gong Fan   +9 more
doaj   +1 more source

Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights

Frontiers in Pharmacology, 2022
Sorafenib, a multi-kinase inhibitor with antiangiogenic, antiproliferative, and proapoptotic properties, is the first-line treatment for patients with late-stage hepatocellular carcinoma (HCC).
Xinchen Tian, Ting-Ting Yan, Fen Liu, Qingbin Liu, Jing Zhao, H. Xiong, Shulong Jiang   +6 more
semanticscholar   +1 more source